Rezultaty - Dana C. Miskulin
- Rezultaty 1 - 20 Rezultaty od 35
- Idź do następnej strony
-
1
-
2
-
3
-
4
-
5
Ergocalciferol Supplementation in Hemodialysis Patients With Vitamin D Deficiency: A Randomized Clinical Trial od Dana C. Miskulin, Karen M. Majchrzak, Hocine Tighiouart, Richard S. Muther, Toros Kapoian, Doug Johnson, Daniel E. Weiner
Wydane 2015Artigo -
6
-
7
-
8
-
9
-
10
-
11
Comorbidity assessment using the Index of Coexistent Diseases in a multicenter clinical trial od Dana C. Miskulin, Nicolaos V. Athienites, Guofen Yan, Alice Martin, Daniel B. Ornt, John W. Kusek, Klemens B. Meyer, Andrew S. Levey, for the Hemodialysis Study Group
Wydane 2001Artigo -
12
Age-related Blood Pressure Patterns and Blood Pressure Variability among Hemodialysis Patients od Mark Rohrscheib, Orrin Myers, Karen S. Servilla, Christopher Adams, Dana C. Miskulin, Edward J. Bedrick, William C. Hunt, Douglas E. Lindsey, Darlene Gabaldon, Philip G. Zager
Wydane 2008Artigo -
13
-
14
The Influence of Age on Changes in Health‐Related Quality of Life over Three Years in a Cohort Undergoing Hemodialysis od Mark Unruh, Anne B. Newman, Brett Larive, Mary Amanda Dew, Dana C. Miskulin, Tom Greene, Srinivasan Beddhu, Michael V. Rocco, John W. Kusek, Klemens B. Meyer
Wydane 2008Artigo -
15
Total Kidney Volume Is a Prognostic Biomarker of Renal Function Decline and Progression to End-Stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease od Ronald D. Perrone, Samer Mouksassi, Klaus Romero, Frank S. Czerwiec, Arlene B. Chapman, Berenice Y. Gitomer, Vicente E. Torres, Dana C. Miskulin, Steve Broadbent, Jean‐Francois Marier
Wydane 2017Artigo -
16
COVID-19 Among US Dialysis Patients: Risk Factors and Outcomes From a National Dialysis Provider od Caroline M. Hsu, Daniel E. Weiner, Gideon Aweh, Dana C. Miskulin, Harold J. Manley, Carol Stewart, Vlad Ladik, John Hosford, Edward C. Lacson, Douglas Johnson, Eduardo Lacson
Wydane 2021Artigo -
17
Which Targets in Clinical Practice Guidelines Are Associated with Improved Survival in a Large Dialysis Organization? od Francesca Tentori, William C. Hunt, Mark Rohrscheib, Min Zhu, Christine A. Stidley, Karen S. Servilla, Dana C. Miskulin, Klemens B. Meyer, Edward J. Bedrick, Howard Johnson, Philip G. Zager
Wydane 2007Artigo -
18
Primary results of the randomized trial of metformin administration in polycystic kidney disease (TAME PKD) od Ronald D. Perrone, Kaleab Z. Abebe, Terry Watnick, Andrew D. Althouse, Kenneth R. Hallows, Christina M. Lalama, Dana C. Miskulin, Stephen L. Seliger, Cheng Tao, Peter C. Harris, Kyongtae Ty Bae
Wydane 2021Artigo -
19
Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months od Caroline M. Hsu, Daniel E. Weiner, Harold J. Manley, Gideon Aweh, Vladimir Ladik, Jill Frament, Dana C. Miskulin, Christos Argyropoulos, Kenneth Abreo, Andrew I. Chin, Reginald Gladish, Loay Salman, Doug Johnson, Eduardo Lacson
Wydane 2022Artigo -
20
BP in Dialysis: Results of a Pilot Study od Dana C. Miskulin, Jennifer Gassman, Ronald Schrader, Ambreen Gul, Manisha Jhamb, David W. Ploth, Lavinia Negrea, Raymond Y. Kwong, Andrew S. Levey, Ajay Singh, Antonia Harford, Susan Paine, Cynthia Kendrick, Mahboob Rahman, Philip G. Zager
Wydane 2017Artigo
Narzędzie wyszukiwania:
Podobne hasła
Internal medicine
Medicine
Dialysis
Kidney disease
Hemodialysis
Autosomal dominant polycystic kidney disease
Intensive care medicine
Endocrinology
Confidence interval
Disease
Kidney
Polycystic kidney disease
Renal function
Blood pressure
Environmental health
Population
Pathology
Proportional hazards model
Surgery
Cardiology
Hazard ratio
Urology
Adverse effect
Alternative medicine
Clinical trial
Comorbidity
Gastroenterology
Nursing
Randomized controlled trial
Antibody